View Older Stories
-
BD completes spin-off and merger of biosciences unit with Waters Corp
-
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
-
Citi Resumes Becton Dickinson (BDX) at Buy
-
Waters to merge with BD's biosciences unit in $17.5 billion deal
-
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Citi Downgrades Becton Dickinson (BDX) to Neutral
-
BD to Present at Investor Healthcare Conferences
-
Becton Dickinson (BDX) to Separate Biosciences and Diagnostic Solutions Business
-
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
-
Citi Upgrades Becton Dickinson (BDX) to Buy
-
Becton Dickinson (BDX) to Acquire Edwards Lifesciences' (EW) Critical Care Product Group for $4.2B Cash
-
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
-
Citi Issues 90-Day Upside Catalyst Watch on Becton Dickinson (BDX)
-
Citi Opens 90-Day Upside Catalyst Watch on Becton Dickinson (BDX)
-
BD to Present at Investor Healthcare Conferences
-
BD Announces Pricing of the Tender Offers
-
BD Announces Early Tender Results and Upsizing of Offer SubCap
-
BD Announces Tender Offers for Outstanding Debt Securities
-
BD Announces Pricing of Tender Offers
-
Becton, Dickinson and Company Announces Early Tender Results
-
BD Announces Upsizing of Tender Offers
-
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
-
Becton Dickinson (BDX) Prices $1.5B Common Share Offering at $240/Sh; Announces Pricing of $1.5B Mandatory Convertible Preferred Shares
-
BD Prices Offerings of $1.5 Billion of Common Stock and $1.5 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock
-
Becton Dickinson (BDX) PT Raised to $296 at Citi
-
Becton Dickinson (BDX) PT Lowered to $256 at Citi
-
Becton Dickinson (BDX) PT Lowered to $279 at Citi
-
Becton Dickinson (BDX) PT Raised to $289 at Citi
-
Becton Dickinson (BDX) PT Raised to $283 at Citi
-
Becton Dickinson (BDX) PT Raised to $274 at Citi
-
Becton Dickinson (BDX) PT Raised to $258 at Citi
-
UPDATE: Citi Upgrades Becton Dickinson (BDX) to Buy
-
Citi Upgrades Becton Dickinson (BDX) to Neutral, Boosts Price Target
-
BD Announces Exercise of Option to Purchase Additional Shares by Underwriters of Public Equity Offerings Increasing Total Gross Proceeds to $4.95 Billion
-
Becton Dickinson (BDX) Prices $2.25B Common Offering at $176.50/Sh; Also Prices $2.25B Convertible Preferred Offering at $50/Sh
-
BD Prices Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock
-
Becton Dickinson (BDX) Commences $2.25B Offering of Common Stock and $2.25B Offering of Mandatory Convertible Preferred Stock
-
BD Announces Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock
-
Becton Dickinson (BDX) to Acquire C.R. Bard (BCR) for $24 Billion
-
BD To Acquire Bard For $24 Billion
-
BD Announces Pricing of Tender Offers
-
BD Announces Early Tender Results and Upsizing of Maximum Tender Offers
-
BD to Offer Euro-denominated Senior Unsecured Notes
-
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
-
Notable Analyst Rating Changes 9/23: (PRU) (KS) (COG) Upgraded; (BDX) (AGR) (RDC) Downgraded
-
Citi Downgrades Becton Dickinson (BDX) to Sell
-
Notable Analyst Rating Changes 2/11: (TWX) (BDX) (LVLT) Upgraded; (V) (SEMI) (ARMH) Downgraded
-
Citi Starts Becton Dickinson (BDX) at Neutral
-
Notable Analyst Rating Changes 12/26: (DWA) (BDX) (BHP) Upgraded; (AGU) (CUB) (SLCA) Downgraded

